Drugs / larotaxel
larotaxel
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00327743 | Aug 2006 → Mar 2009 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00485979 | Jun 2007 → Aug 2010 | breast neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00387907 | Oct 2006 → Mar 2008 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00386685 | Jul 2006 → Oct 2008 | breast neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00087958 | Aug 2004 → Feb 2007 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00625664 | Feb 2008 → Feb 2011 | urinary bladder neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00417209 | Dec 2006 → Jul 2009 | pancreatic neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00081796 | Apr 2004 → Sep 2006 | breast cancer, metastatic neoplasm | Sanofi | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | larotaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00327743 ↗ |
| Known as | RPR109881 | “larotaxel (RPR109881, XRP9881)” NCT00081796 ↗ |
| Known as | XRP9881 | “larotaxel (RPR109881, XRP9881)” NCT00081796 ↗6“Drug: larotaxel (XRP9881)” NCT00485979 ↗ “larotaxel (XRP9881)” NCT00387907 ↗ “Larotaxel (XRP9881)” NCT00417209 ↗ “larotaxel (XRP9881)” NCT00625664 ↗ “larotaxel (XRP9881)” NCT00386685 ↗ |
| Modality | Small molecule | — CHEMBL4279455 ↗ |
| Route | Intravenous | “The investigational drug in this clinical trial is a chemotherapy drug given through the vein once every three weeks.” NCT00081796 ↗ |